Allopurinol and Pathogenesis of Cirrhosis

Tanta University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Cirrhoses, Liver

Treatments: Drug: Allopurinol Tablet; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07033533

ALLOU

Details and patient eligibility

About

Hepatic decompensation is a common healthcare issue

. This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Enrollment: 100 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18-75 both sex

Exclusion criteria

• active GIT bleeding

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Description:

placebo

Treatment:

Drug: Placebo

allopurinol

Active Comparator group

Treatment:

Drug: Allopurinol Tablet